Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CRAT | P43155 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 6/20 | 0.31 |
| ▸ | ECE1 | P42892 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557965 | 1.00 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL25582806 | 0.84 | CASP1 (0.34) | ECE1 | |
| SCHEMBL23288380 | 0.83 | ALDH1A1 (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL8360127 | 0.81 | CASP3 (0.43) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4599097 | 0.81 | CASP3 (0.43) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4599055 | 0.81 | CASP3 (0.43) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7352207 | 0.80 | DPP4 (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL11363519 | 0.80 | DPP4 (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1995209 | 0.80 | CTSK (0.39) | CTSK | |
| SCHEMBL25582500 | 0.79 | PAX8 (0.46) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010655-A1 | Stationary phases and a purification process using the stationary phases | MERCK & CO., INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1663275-A2 | STATIONARY PHASES AND A PURIFICATION PROCESS USING THE STATIONARY PHASES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026323-A2 | STATIONARY PHASES AND A PURIFICATION PROCESS USING THE STATIONARY PHASES | MERCK & CO., INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010655-A1 | Stationary phases and a purification process using the stationary phases | VIP, LPXN, PROKR1 | KDM4E 4574/4885MAPT 4796/4885THRB 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.